Supported by

Catalogue of collaboration profiles

back to list
Company

Licentia Ltd

Street
Tukhomankatu 8 A
ZIP Code
00290
City
Helsinki
Country
Finland


Company Profile:
Licentia is Finland’s leading full-service health care technology and knowledge transfer Company specializing in valuation, licensing, and commercialization of Intellectual Property.

We have long-term collaborations with leading universities, research organizations, inventors and technology companies.

Our unique combination of knowledge of the health care industry, technological expertise and understanding of the market with the ability to fund selected IP through development and commercialization assures that we offer high quality, low risk partnership.
Profiltitel

Novel Pim kinase inhibitors with demonstrated activity in cell culture (Code: 3404)

What we offer:
Potent inhibitors of one or more Pim kinase to be used in the treatment, prevention or alleviation of human diseases associated with overexpression of Pim kinases, such as cancers and metabolic syndrome.

The present compounds are potent and specific inhibitors of some or all of the three Pim family kinases, and they can efficiently block several Pim-dependent cellular functions. For instance, they are able to inhibit phosphorylation of Pim substrates and abrogate the anti-apoptotic effects of Pim kinases in cytokine-deprived myeloid cells. Furthermore, they are able to significantly inhibit proliferation of lymphoblastoid cell lines (LCLs) that have been infected and immortalized by Epstein-Barr virus (EBV), but they may also have more general anti-cancer activity. Moreover, the present Pim kinase inhibitors are able to inhibit migration of adherent cancer cells, suggesting that they could reduce the ability of these cells to form fatal metastases. Thus, the present cell-permeable pan-Pim inhibitors can be used not only as efficient research tools, but also as promising lead compounds for developing drugs against tumours overexpressing Pim kinases.

What are we looking for:
Potential partner profile:
1. INDUSTRY
2. BIOTECH COMPANY
3. FURTHER DEVELOPMENT

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

Profiltitel

New fibre-reinforced composite for cranio-maxillofacial (CMF) and for next generation dental implants (Code: 3381)

What we offer:
The use of reinforced composites made of particulate fillers or reinforcing fibres has been gaining popularity in dental and medical fields. Several fibre reinforced composites are already known. The state-of-the-art fibre reinforced composites yield high strength properties and by selecting the multiphase resin matrix for the composite, the handling characteristics of the composite can be considerably improved.

On the other hand, a lot of development has occurred with bioactive materials, namely bioactive ceramics and glass and sol-gel processed silica. These materials can be used to achieve attachment of e.g. bone to a biomaterial surface after the material has been put in contact with tissue. An additional advantage of bioactive glass is its antimicrobial effect on the microbes existing for instance in sinuses of a bone. The need and indications for development of new kinds of materials result from disadvantages of the use of allografts. Risks for transmittable diseases (HIV, Creutzfeld-Jacob´s disease, etc) are related to allografting. Metals are not bioactive or osteoconductive, and their use results in stress shielding phenomena and bone atrophy of the adjacent bone. Metal implants cause also severe problems in magnetic resonance imaging (MRI) when diagnosing diseases of patients. These main disadvantages are well documented in large clinical series.


Although the current trend in biomaterial research is in biodegradable polymers and composites, there is a constant need for biostabile materials to be used in repairs of large bone defects. Key issues in biostabile composite development are biomechanical properties (E-modulus, structural stiffness, load-bearing capacity), porosity and bioactivity of the material.

What are we looking for:
- TYPE OF PARTNER SOUGHT:
Industry

- SPECIFIC AREA OF ACTIVITY OF THE PARTNER:
Medical technology companies which are engaged in developing, manufacturing and marketing cranio-maxillo-facial, dental implants and composite implants for surgical purposes, such as for bone grafting and as scaffold for stem cell seeding..

- TASK TO BE PERFORMED:
Further testing and development of innovation.

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

Profiltitel

Circulating oxidized HDL and LDL lipids as biomarkers of cardiac and metabolic diseases (Code: 3346)

What we offer:
A Finnish invention, LDL-BDC (low-density lipoprotein baseline diene conjugation) is a novel clinically applicable method for direct determination of oxidised lipids in circulating LDL. Development of the method is based on experience from a vast number of in vitro and ex vivo studies. The LDL-BDC assay is fast and simple to perform with equipment generally available in clinical laboratories. A prototype of reagent kit for the LDL-BDC assay has already been prepared and validated, and it is possible to continue development of the methodology into a laboratory analyser.

Procedure of the LDL-BDC assay:
* Mix serum sample with LDL precipitating reagent
* Centrifuge 15 min x 1500 g
* Remove supernatant and re-dissolve precipitated LDL
* Mix obtained LDL solution with lipid extraction reagent
* Centrifuge 3 min x 1500 g
* Read absorbance in upper phase

What are we looking for:
TYPE OF PARTNER SOUGHT:
Industry
- SPECIFIC AREA OF ACTIVITY OF THE PARTNER:
Diagnostic industry

TASK TO BE PERFORMED:
Partner willing to further develop and utilise (market and sell) this oxidised LDL kit in the USA and worldwide.

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

Profiltitel

A rapid flow cytometric method for distinguishing bacterial from viral infection (Code: 3327/ 3386)

What we offer:
In their previous study the inventors have shown that the neutrophil complement receptor 1 (CR1) can be of value in the etiological diagnosis of bacterial infection (EP patent No. 1 405 078 and US patent No. 7645591). Neutrophil CR1 based differentiation between bacterial and viral infections was further improved by generating the clinical infection score (CIS) point, which incorporates the quantitative analysis of CR1 on neutrophils, neutrophil count, erythrocyte sedimentation rate (ESR), and serum C-reactive protein
(CRP), and displays over 95% sensitivity and specificity in distinguishing between bacterial and viral infections [1-3].

The greatest weakness of the CIS point method is that it incorporates the results of four separate measurements, making the method quite complex and time-consuming. The inventors thus propose a novel flow cytometric (Bacterial Infection Score (BIS) point) method, which is considerably faster (diagnosis in about 1 hour) than traditional methods (diagnosis in several hours or even days) in distinguishing between bacterial and viral infections. The BIS point method is carried out by simultaneously determining the expression of several leukocyte surface receptors, on the surface of peripheral blood neutrophils and monocytes. The receptors to be analysed (CR1 being one of them) are commonly known receptors of neutrophils or monocytes involved in phagocytosis and complement function.

What are we looking for:
TYPE OF PARTNER SOUGHT:
- Industry

SPECIFIC AREA OF ACTIVITY OF THE PARTNER:
- Diagnostic companies

TASK TO BE PERFORMED:
- Further develop the discovery and transfer it into a diagnostic test

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

Profiltitel

Method to guide optimal therapy choice in cancer (Code: 3360)

What we offer:
Breast cancer is the most common cancer type among women worldwide, and the second leading cause of death. Its prognosis is influenced by tumor stage, grade, HER2- and hormonal receptor status, which are used to classify the tumor and to choose the individual treatment regimen for each patient.

To improve the outcome of individual breast cancer therapy, novel biomarkers are needed to define subsets of patients who benefit from a given treatment regimen. Such markers might arise from genetic variation, which - in addition to breast cancer susceptibility - may play a role in the progression of the disease, response to treatment and overall outcome.

The present technology is based on a discovery of biomarker, NQO1*2 genotype, that appears to strongly predict how breast cancer patients will respond to a common form of chemotherapy.

The NQO1 enzyme has previously been shown to guard cells against oxidative stress and to help prevent the spread of cancer. The NQO1*2 variant disables the production of the NQO1 enzyme. An analysis of DNA data from more than 1,000 patients treated for breast cancer revealed that the presence of NQO1*2 was shown to strongly worsen the survival chances for those who were treated with an anthracycline-based chemotherapy. Patients who had a double copy of NQO1*2 in their genome had only a 17 % survival rate while those who had only a single copy, or did not have a variant, had a survival rate of 75 %. Importantly when patients with this NQO1*2 variant were treated with a non-anthracycline containing regimen they had outcomes that were equivalent to patients without the NQO1*2 variant.

What are we looking for:
TYPE OF PARTNER SOUGHT:
Industry

SPECIFIC AREA OF ACTIVITY OF THE PARTNER:
Diagnostics companies

TASK TO BE PERFORMED:
Further develop the discovery and transfer it into a diagnostic test

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

Profiltitel

Serum biomarker for Mitochondrial Respiratory Chain Dysfunction in skeletal muscle which does not require muscle biopsy (Code: 3394)

What we offer:
Progressive dysfunction of the mitochondrial respiratory chain (RC) is a common cause of severe children’s multisystem disorders, and a variety of adult-onset myopathies and neurodegenerative disorders. Current methods of diagnosis involve clinical evaluation with and a key diagnostic method is muscle biopsy: an invasive and costly intervention. A patient may undergo several muscle biopsies during the course of their disease. In the Western world, over hundred thousand muscle biopsies are taken every year when mitochondrial disease is suspected.

What are we looking for:
TYPE OF PARTNER SOUGHT:
Industry

SPECIFIC AREA OF ACTIVITY OF THE PARTNER:
Diagnostics companies

TASK TO BE PERFORMED:
Further develop the discovery

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

Profiltitel

Method to select appropriate patient management in gram-negative infections (Code: 3395)

What we offer:
With the increasing development of multi-resistant Gram-negative infections, the management of patients is becoming more difficult and expensive. Isolation facilities are limited in most hospitals. New antibiotics, carbapenems, have been developed and are reserved for severe cases but resistance is developing even for these. It is important to determine which patients need to receive these new antibiotics and which will respond to more conventional therapy.

Biochemical methods maybe insufficient to identify certain carbapenem resistance mechanisms. They are often hampered by masking of overlapping resistance mechanisms within the same strain. Metallo β-lactamases can be identified with carbapenem +EDTA-based inhibition test, whereas some serine β-lactamases, especially KPC and GES, may be difficult to detect by biochemical methods.

To supplement these phenotypic gaps, a Real Time PCR was developed for screening of virtually all clinically significant carbapenem resistance genes among Enterobacteriaceae, Acinetobacter sp. and Pseudomonas sp. The results, including exact molecular mechanisms, can be used to determine therapeutic choice and patient management: which patients need to be isolated and which can be treated in an open ward.

What are we looking for:
TYPE OF PARTNER SOUGHT:
Industry

SPECIFIC AREA OF ACTIVITY OF THE PARTNER:
Diagnostics companies

TASK TO BE PERFORMED:
Further develop the discovery and transfer it into a diagnostic test

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

Profiltitel

An agent to increase the bioavailability and decrease the metabolism of CYP2C8-substrate drugs – a new option to improve pharmacokinetics. (code: 3403)

What we offer:
CYP2C8 is an important enzyme for the elimination of many drugs, and sometimes, for the formation of toxic metabolites. The activity of CYP2C8 varies genetically and due to certain drug interactions leading to unpredictable pharmacokinetics and safety problems of its substrate drugs.

This invention involves a compound which can be used in formulations to optimize the bioavailability and plasma profile of CYP2C8-substrate drugs, and for the prevention of formation of CYP2C8-mediated toxic metabolites.

The compound
- can be used in small doses (mg-level), being well suitable to oral formulations
- has a long-lasting effect on CYP2C8, i.e. dosing thrice, twice or once daily is possible as an enhancer of CYP2C8-substrate drugs
- has an excellent safety profile
- has been studied in humans, documented clinically
- increases the peak concentration, bioavailability and / or prolongs the elimination half-life of CYP2C8 substrates
- prevents CYP2C8-mediated formation of toxic metabolites

What are we looking for:
TYPE OF PARTNER SOUGHT:
Industry

SPECIFIC AREA OF ACTIVITY OF THE PARTNER:
Pharma companies

TASK TO BE PERFORMED:
Further develop the discovery

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

Profiltitel

New biocompatible inorgano-bioorganic nanocomposites (Code: 3385)

What we offer:
The invention comprises a preparation method of a uniform nanocomposite material using synthetic layered double hydroxides (LDH) and natural polysaccharides. The composite is synthesised in-situ not by mechanical mixing of the components, co-precipitation or ion exchange techniques.

Properties of elements of the composite are controlled and predictable. Synergistic combination of the functional properties of the components ensures a myriad of potential applications for novel uniform LDH-polysaccharide nanocomposite materials, making them a natural fit for sustainable development.

What are we looking for:
TYPE OF PARTNER SOUGHT:
Industry

SPECIFIC AREA OF ACTIVITY OF THE PARTNER:
Biomaterial companies

TASK TO BE PERFORMED:
Further develop the discovery

Collaboration sought:
  • Licence


Responsible

Jyrki Ingman

back to list

Participants

Enterprise Europe ScotlandAboleo LtdAccuro BiologicsAlliance BootsBeta TechnologyBitWiseFW Medical LLPInnova Partnerships LtdInterface-The knowledge connection for businessMarks and Clerk LLPMcClure Naismith LLPThe Medical Device Company LtdQuantics Consulting LtdScottish Health InnovationsPharmalinksSistemic LtdStrathclyde Institute of Medical DevicesSynthetic Nanomachines LtdTissue SolutionsUniversity of AberdeenEllis IP LtdPharmacells LtdCeltic CatalystsPharmaceutical eConsultingWeatherologyControlled TherapeuticsSphere Fluidics LimitedHighland Clinical Research FacilityMoorfields PharmaceuticalsEdinburgh Science Trianglebeocarta LtdRostiShore DesignPomBioTech GmbHIMG Innovations-Management  GmbH/ Enterprise Europe NetworkThe Eurotactics ConsultancyIBA GmbHSGS Life Science ServicesOnorach  ClinicalWideblueEnterprise Europe YorkshireAptuit ConsultingMosaigen/Endeavour CapitalEscubed LtdEulysis Ltd.Raumedic LtdCatalent Pharma SolutionsEscubed LtdUniversity of Aberdeen Research and InnovationSPRI - Basque Enterprise Europe NetworkLicentia LtdTake The WindRoslin CellabMoredun ScientificEnterprise Europe East of EnglandAvantiCell ScienceXeroshield Ltd.ImmunoSolv LimitedLeoben Research LimitedPRAXI / HELP-FORWARD Network &The Hellenic BioClusterEMBIO Diagnostics Ltd


© 2010 ConVerve GmbH | all rights reserved